IASO Bio Receives Orphan Drug Designation From the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (ODD) by the Ministry of Food and Drug S…

FDA Eases REMS Protocols and Travel Restrictions for CAR-T Cancer Therapies

The U.S. Food and Drug Administration (FDA) has taken s […] The post FDA Eases REMS Protocols and Travel Restrictions for CAR-T Cancer Therapies first appeared on GeneOnline News. The post FDA Eases REMS Protocols and Travel Restrictions for CAR-T Cancer Therapies appeared first on GeneOnline News.

FDA Orphan Drug Status Granted for CAR T-Cell Therapy in Malignant Gliomas

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.